GW Pharma (GWPH) Posts Q3 Loss of 6c/Share; THCV Phase 2 Missed Primary Endpoint in T2D

August 9, 2016 7:03 AM EDT
Get Alerts GWPH Hot Sheet
Trade GWPH Now!
Join SI Premium – FREE

News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.

GW Pharma (NASDAQ: GWPH) reported Q3 EPS of ($0.06), $1.15 better than the analyst estimate of ($1.21). Revenue for the quarter came in at $3.1 million versus the consensus estimate of $3.63 million.


  • Epidiolex┬« (CBD) orphan epilepsy program in Dravet syndrome, Lennox-Gastaut Syndrome (LGS), Tuberous Sclerosis Complex (TSC) and infantile spasms (IS)
    • Phase 3 development programs:
      • Positive results in first Phase 3 Dravet syndrome trial
      • Positive results in first Phase 3 LGS trial
      • Data presentations expected at upcoming American Epilepsy Society Annual Meeting in December
      • Positive Dravet syndrome Pre-NDA meeting held with FDA
      • NDA on track for H1 2017 submission for both Dravet and LGS indications
      • Data from second LGS trial expected at end of Q3
      • Second Phase 3 Dravet syndrome trial ongoing
      • Phase 3 trial in TSC ongoing
      • Phase 3 trial in IS to commence in Q4 2016
    • Expanded access program and open label extension:
      • Over 1,000 patients now on Epidiolex treatment under Expanded Access Treatment INDs, U.S. State programs, and open label extension trial
  • Advanced clinical programs in multiple cannabinoid pipeline product candidates:
    • CBDV Phase 2 partial-onset epilepsy study in adults ongoing. Part A complete and Part B underway with data expected H1 2017
    • CBDV pre-clinical research ongoing within field of autism spectrum disorders. Initial open-label clinical evaluation expected to commence in H2 2016, with Phase 2 trials expected to commence in H1 2017
    • Neonatal Hypoxic-Ischemic Encephalopathy (NHIE) intravenous CBD Phase 1 clinical program expected to commence in Q4 2016
      • Orphan Drug and Fast Track Designations granted from FDA and EMA
    • THC:CBD Phase 1b/2a study for the treatment of Recurrent Glioblastoma Multiforme (GBM) fully enrolled with data expected in Q4 2016
    • Sativex┬« Phase 2 study in children with spasticity due to cerebral palsy fully enrolled with data expected Q4 2016
    • THCV Phase 2 study in type 2 diabetes completed, primary endpoint not achieved

For earnings history and earnings-related data on GW Pharma (GWPH) click here.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Corporate News, Earnings, FDA

Related Entities


Add Your Comment